Best Hospitals for Vaginal Cancer Treatment in Bengaluru, India

Vaginal cancer accounts for approximately 1–2% of all gynecologic malignancies, with squamous cell carcinoma (SCC) comprising 85–90% of cases and adenocarcinoma, melanoma, and sarcoma constituting the remainder. The vaginal epithelium is anatomically contiguous with the cervix superiorly and the vulva inferiorly, meaning malignant transformation — most frequently driven by persistent high-risk human papillomavirus (HPV) infection, particularly genotypes 16 and 18 — can produce lesions across a spectrum from vaginal intraepithelial neoplasia (VAIN) to invasive carcinoma. Because the vagina lies in close proximity to the bladder, urethra, rectum, and pelvic sidewall vasculature, even localized disease carries significant implications for organ function, urinary and bowel continence, and sexual health.

• Confirmed histopathologic diagnosis of vaginal carcinoma (SCC, adenocarcinoma, or other histology) on colposcopy-directed biopsy or EUA biopsy
• FIGO Stage I–IVA disease being considered for curative-intent treatment; Stage IVB patients evaluated for palliative or systemic protocols
• ECOG Performance Status 0–2 (sufficient functional reserve for surgery or chemoradiation)
• Adequate bone marrow reserve: ANC ≥1,500/µL, platelets ≥100,000/µL, hemoglobin ≥9 g/dL (for cisplatin eligibility)
• Adequate renal function: GFR ≥50 mL/min (creatinine clearance assessed before platinum-based chemotherapy)
• +6 more

Surgical Approaches

Radical Vaginectomy: Indicated for Stage I upper-vaginal SCC in patients without prior irradiation. En-bloc resection of the vagina with adequate margins (≥1 cm), often combined with pelvic lymph node dissection (sentinel node biopsy increasingly utilized). Vaginal reconstruction using split-thickness skin grafts, Singapore (pudendal thigh) flaps, or gracilis myocutaneous flaps is performed concurrently by reconstructive surgeons to preserve sexual function.

Robotic-Assisted Radical Vaginectomy + Pelvic Lymphadenectomy (da Vinci Xi Platform): Available at select high-volume centers in India (Tata Memorial, Apollo, Manipal) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City). Offers 10× magnified 3D visualization, wristed instrumentation enabling precise dissection in the narrow bony pelvis, reduced blood loss (mean 150–200 mL vs. 400–600 mL open), shorter hospitalization, and faster return to ambulation. Particularly advantageous for upper-vaginal tumors near the bladder trigone.

Pelvic Exenteration: Reserved for recurrent or persistent central disease after prior chemoradiation. Anterior exenteration (bladder + vagina), posterior exenteration (rectum + vagina), or total pelvic exenteration depending on organ involvement. Requires ileal conduit or neobladder reconstruction and colostomy where applicable. Performed by multidisciplinary surgical teams.

STEP 1 — PRE-ARRIVAL CONSULTATION (Weeks 1–2 before travel) Patients submit existing biopsy reports, imaging (MRI/PET-CT), operative notes, and pathology to GAF Healthcare's oncology coordination team. A virtual multidisciplinary tumor board (gynecologic oncologist, radiation oncologist, medical oncologist, radiologist) reviews the case and provides a written treatment recommendation and itemized cost estimate within 48–72 hours. Visa documentation (e-Medical Visa for India; UAE entry visa support) is initiated simultaneously.

STEP 2 — ARRIVAL AND STAGING WORKUP (Days 1–5 in country) Upon arrival, GAF Healthcare's ground team facilitates airport pickup and hotel/hospital guest house check-in. The patient undergoes repeat or supplementary staging: MRI pelvis with gadolinium contrast, PET-CT if not recently performed (within 4 weeks), examination under anesthesia (EUA) with colposcopy, cystoscopy (Stage ≥III), CBC, CMP, GFR, SCC antigen, CA-125, and biomarker profiling (HPV genotype, PD-L1 CPS, MSI/MMR). An anesthesiology pre-assessment is completed for surgical candidates.

STEP 3 — MULTIDISCIPLINARY TUMOR BOARD CONFIRMATION (Day 5–7) All staging data are presented at the institutional tumor board. Final treatment pathway is confirmed (surgery vs. definitive chemoradiation vs. combined approach), and consent is obtained. Radiation planning CT simulation with vaginal fiducial marker insertion is performed for chemoradiation candidates; surgical scheduling is confirmed for operative candidates.